Fig. 4: NPC grafted into striatal stroke generate astroglia that reduce fibrotic scar and bridge lesions.
a Schematic summarizing experimental approach for evaluating NPC grafting in mouse striatal stroke. b Survey IIHC images of stroke lesions at 2 weeks comparing effect of hydrogel (DCHMO) alone or grafted HA-positive NPC on stroke lesion phenotype. NPC grafted lesions show Gfap-positive lesions with reduced Cd13-positive tissue in non-neural lesion core. c Quantification of Gfap and Cd13 intensity at stroke lesions as a function of the radial distanced from the center of the lesion with mean±s.e.m. (s.e.m represented as shaded region). d, e Survey IHC images of stroke lesions at 4 weeks (d) and 8 weeks (e) comparing the effect of grafted HA-positive NPC on stroke lesion phenotype. f Quantification of total Cd13 at stroke lesion cores at 2 weeks after L-NIO injection for stroke only, hydrogel (DCHMO) alone, and NPC grafting by performing area under the curve (AUC) calculations of Cd13 traces in c. (N = 4 for L-NIO only, N = 5 for gel, N = 6 NPC graft). ***p value < 0.0005. One-way ANOVA with Tukey multiple comparison test. g Quantification of total Gfap at stroke lesions at 2 weeks after L-NIO injection for stroke only, hydrogel (DCHMO) alone, and NPC grafting by performing AUC calculations of Gfap traces in c. (N = 4 for L-NIO only, N = 5 for gel, N = 6 NPC graft) Using Gfap-HA colocalization (see Supplementary Fig. 11) the total Gfap contribution from the NPC graft and host astrocytes in the NPC graft group was determined. h Quantification of total Cd13 at stroke lesion cores at 2, 4, and 8 weeks after L-NIO injection for stroke only and NPC grafting. (N = 4, 5, 6 for L-NIO only at 2, 4, and 8 weeks, N = 6, 4, 5 for NPC grafts at 2, 4, and 8 weeks). ***p value < 0.0001, **p value < 0.005, *p value < 0.05. Two-way ANOVA with Tukey multiple comparison test. All graphs are mean ± s.e.m. AU arbitrary units.
